AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in high-risk group
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SARS-CoV-2 seroprevalence
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity in males
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity in workers residing in high-prevalence areas
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity in supporting services workers compared to doctors
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity in administration staff compared to doctors
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity in nurses compared to doctors
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of previously undetected infection
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: High district prevalence as a factor for seropositivity in low-risk group
Number of subjects: 1078
Study 36299404 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital scan
Number of subjects: 96
Study 36299404 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 96
Study 36462032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remimazolam (Group H, 0.08 mg/kg)
Number of subjects: 204
Study 36462032 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose remimazolam (Group M, 0.06 mg/kg)
Number of subjects: 204
Study 36462032 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, 0.9% saline)
Number of subjects: 204
Study 36462032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose remimazolam (Group L, 0.04 mg/kg)
Number of subjects: 204
Study 36462032 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) for elderly patients
Number of subjects: 204
Study 36462032 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose remimazolam (Group M)
Number of subjects: 204
Study 33168945 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-based cognitive remediation (ABCR)
Number of subjects: 45
Study 33168945 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 45
Study 34415830 — intervention group
Group type: EXPERIMENTAL
Intervention: mnemoPQQ® (PQQ disodium salt: 21.5 mg/day)
Number of subjects: 64
Study 34415830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 34349371 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask (Group M)
Number of subjects: 89
Study 34349371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) (Group L)
Number of subjects: 89
Study 35410931 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (one home visit, unsupervised exercise training, and motivational telephone calls)
Number of subjects: 490
Study 35410931 — intervention group
Group type: COMPARATOR
Intervention: Centre-based pulmonary rehabilitation (supervised exercise training for 8 weeks)
Number of subjects: 490
Study 35410931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation
Number of subjects: 490
Study 32460297 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm application
Number of subjects: 100
Study 32460297 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 34081062 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional assistance to the closest AED
Number of subjects: 35
Study 34081062 — intervention group
Group type: COMPARATOR
Intervention: No directional assistance
Number of subjects: 35
Study 33453714 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 0
Study 33453714 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (Control)
Number of subjects: 0
Study 32713115 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic Stent (PS)
Number of subjects: 53
Study 32713115 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered Self-Expandable Metal Stent (uSEMS)
Number of subjects: 53
Study 32713115 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 53
Study 34351562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano or micro zinc oxide (49, 74, 99, and 124 mg ZnO/kg diet)
Number of subjects: 288
Study 34351562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano or micro zinc oxide
Number of subjects: 288
Study 34351562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano zinc oxide
Number of subjects: 288
Study 34351562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano and micro zinc oxide
Number of subjects: 288
Study 34351562 — intervention group
Group type: COMPARATOR
Intervention: Control non-supplemented diet (24 mg/kg)
Number of subjects: 288
Study 32847626 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours
Number of subjects: 80
Study 32847626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing taxes on the product mentioned in the message
Number of subjects: 1850
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting rid of price discounts and special offers on the product mentioned in the message
Number of subjects: 1850
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting rid of low-cost versions of the product mentioned in the message
Number of subjects: 1850
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Frames regarding children and reducing cancer risk
Number of subjects: 1850
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco policies
Number of subjects: 1850
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol policies
Number of subjects: 1850
Study 33495253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugary drinks/foods policies
Number of subjects: 1850
Study 33077817 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (high-intensity interval aerobic fitness and strength training with nutritional supplement)
Number of subjects: 148
Study 33077817 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone (high-intensity interval aerobic fitness and strength training with placebo)
Number of subjects: 148
Study 35557383 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (Fi O2 = 20.6 ± 0.3%)
Number of subjects: 21
Study 35557383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (Fi O2 = 14.0 ± 0.2%)
Number of subjects: 21
Study 35557383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Normoxia and Hypoxia)
Number of subjects: 21
Study 34063673 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation (PNM) treatment
Number of subjects: 24
Study 34063673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 37728446 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI-based goal-directed fluid management (GDFM)
Number of subjects: 66
Study 37728446 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid management
Number of subjects: 66
Study 32966603 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-enhanced care management
Number of subjects: 40
Study 32966603 — intervention group
Group type: COMPARATOR
Intervention: Telephone care management
Number of subjects: 40
Study 32791721 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (3 ml supernatant of maternal vaginal bacteria)
Number of subjects: 30
Study 32791721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 ml sterile water)
Number of subjects: 30
Study 32791721 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (3 ml supernatant)
Number of subjects: 30
Study 33802181 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 16
Study 33802181 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 16
Study 32463263 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression polygenic risk scores (PRS)
Number of subjects: 0
Study 32463263 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing polygenic risk scores (PRS)
Number of subjects: 0
Study 616858559 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicator-based reminder of catheter removal and standardized Foley care
Number of subjects: 75
Study 616858559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no indicator-based reminder)
Number of subjects: 75
Study 616858559 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 75
Study 616858559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 33896803 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibrations (100 Hz)
Number of subjects: 10
Study 33896803 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 10
Study 32930932 — intervention group
Group type: EXPERIMENTAL
Intervention: 14,552 simple sequence repeat (SSR) markers developed from 21,055 microsatellite repeats using Illumina paired-end sequencing technology.
Number of subjects: 3
Study 32930932 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR markers used to estimate genetic diversity measures.
Number of subjects: 3
Study 32930932 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 primers evaluated in S. persica for cross-transferability.
Number of subjects: 3
Study 34725500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 0
Study 34725500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (Hc)
Number of subjects: 0
Study 34725500 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Mpz)
Number of subjects: 0
Study 34725500 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 34725500 — intervention group
Group type: COMPARATOR
Intervention: Bronchopulmonary dysplasia (BPD) group
Number of subjects: 0
Study 32918971 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 19 Gy HDR implant to the whole prostate (Trial1)
Number of subjects: 147
Study 32918971 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focal DIL boost to at least 23 Gy (Trial2)
Number of subjects: 147
Study 32918971 — intervention group
Group type: COMPARATOR
Intervention: MRI-guided focal DIL boost
Number of subjects: 147
Study 32918971 — intervention group
Group type: COMPARATOR
Intervention: Baseline PSA and Gleason score
Number of subjects: 147
Study 32184185 — intervention group
Group type: EXPERIMENTAL
Intervention: Minesapride 40 mg
Number of subjects: 171
Study 32184185 — intervention group
Group type: EXPERIMENTAL
Intervention: Minesapride 12 mg
Number of subjects: 171
Study 32184185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 32389383 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual resource (video of their own choice)
Number of subjects: 160
Study 32389383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiovisual resource)
Number of subjects: 160
Study 35301041 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + Yoga (n = 32)
Number of subjects: 59
Study 35301041 — intervention group
Group type: COMPARATOR
Intervention: CBT (n = 27)
Number of subjects: 59
Study 32445184 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 3000
Study 32445184 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg
Number of subjects: 3000
Study 32445184 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 210 mg
Number of subjects: 3000
Study 32445184 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 3000
Study 32445184 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 3000
Study 32445184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 32445184 — intervention group
Group type: EXPERIMENTAL
Intervention: OLEs (Open-Label Extensions)
Number of subjects: 3000
Study 33523036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition Muscle Energy Technique (AI-MET)
Number of subjects: 78
Study 33523036 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition Muscle Energy Technique (RI-MET)
Number of subjects: 78
Study 33523036 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 78
Study 32356332 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS with simple chords
Number of subjects: 13
Study 32356332 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS with complex chords
Number of subjects: 13
Study 36498963 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylone 50 mg
Number of subjects: 12
Study 36498963 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylone 100 mg
Number of subjects: 12
Study 36498963 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylone 150 mg
Number of subjects: 12
Study 36498963 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylone 200 mg
Number of subjects: 12
Study 36498963 — intervention group
Group type: COMPARATOR
Intervention: HMMC (compared to methylone)
Number of subjects: 12
Study 33439036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusarium venenatum isolates (6 isolates used for inoculation)
Number of subjects: 600
Study 33439036 — intervention group
Group type: COMPARATOR
Intervention: Non-inoculated controls
Number of subjects: 600
Study 34978858 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic AF screening
Number of subjects: 1000
Study 34978858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematic AF screening)
Number of subjects: 1000
Study 33514270 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 3
Study 33514270 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 3
Study 33514270 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS
Number of subjects: 3
Study 32338589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active control arms)
Number of subjects: 35
Study 33892597 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-style video
Number of subjects: 284
Study 33892597 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheet
Number of subjects: 284
Study 33892597 — intervention group
Group type: COMPARATOR
Intervention: Standard consent process
Number of subjects: 284
Study 32455866 — intervention group
Group type: EXPERIMENTAL
Intervention: soy milk + PS (1.6 g/day)
Number of subjects: 38
Study 32455866 — intervention group
Group type: COMPARATOR
Intervention: soy milk
Number of subjects: 38
Study 35137298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula covered by the surgical facemask
Number of subjects: 27
Study 35137298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula covered by the double‐trunk mask
Number of subjects: 27
Study 35137298 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula alone
Number of subjects: 27
Study 33166056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing (PGx testing)
Number of subjects: 49
Study 33166056 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation group (PGx testing at the beginning of the study)
Number of subjects: 49
Study 33166056 — intervention group
Group type: COMPARATOR
Intervention: Control group (PGx testing at the end of the study)
Number of subjects: 49
Study 33166056 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 poor and intermediate metabolizers after the eighth week of treatment
Number of subjects: 49
Study 35983677 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change intervention (IG)
Number of subjects: 300
Study 33982068 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg of ramosetron (Irribow®) daily for 4 weeks
Number of subjects: 100
Study 33982068 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for 4 weeks
Number of subjects: 100
Study 33289844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (2800 IU/d)
Number of subjects: 623
Study 33289844 — intervention group
Group type: COMPARATOR
Intervention: Standard dose vitamin D3 supplementation (400 IU/d)
Number of subjects: 623
Study 34315522 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified resistant starch (40 g/day)
Number of subjects: 0
Study 34315522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch or regular flour)
Number of subjects: 0
Study 33888589 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT-eligible patients managed with lung-protective ventilation (LPV)
Number of subjects: 1975
Study 33888589 — intervention group
Group type: COMPARATOR
Intervention: RCT-ineligible patients managed with lung-protective ventilation (LPV)
Number of subjects: 1975
Study 33888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients managed by protocol (LPV)
Number of subjects: 1975
Study 33888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Pplat < 30 cmH2O managed by protocol (LPV)
Number of subjects: 1975
Study 35841084 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended professional learning program for educators (12-week duration)
Number of subjects: 313
Study 32664779 — intervention group
Group type: COMPARATOR
Intervention: EMLA® cream
Number of subjects: 30
Study 32664779 — intervention group
Group type: COMPARATOR
Intervention: Cryoanalgesic
Number of subjects: 30
Study 32091560 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh), 4 sessions over 2 months
Number of subjects: 35
Study 32091560 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (manual placebo), 4 sessions over 2 months
Number of subjects: 35
Study 35457698 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 and Level 2 programs
Number of subjects: 3207
Study 35457698 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 program
Number of subjects: 3207
Study 35457698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3207
Study 32079916 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (2 × 5 g·d)
Number of subjects: 25
Study 32079916 — intervention group
Group type: COMPARATOR
Intervention: Alanine supplementation (2 × 5 g·d)
Number of subjects: 25
Study 35670381 — intervention group
Group type: EXPERIMENTAL
Intervention: Journeying through Dementia psychosocial intervention
Number of subjects: 0
Study 33744812 — intervention group
Group type: EXPERIMENTAL
Intervention: abiraterone/prednisone combination
Number of subjects: 63
Study 33744812 — intervention group
Group type: EXPERIMENTAL
Intervention: enzalutamide combination
Number of subjects: 63
Study 33744812 — intervention group
Group type: COMPARATOR
Intervention: radium-223 monotherapy
Number of subjects: 63
Study 33744812 — intervention group
Group type: EXPERIMENTAL
Intervention: all groups
Number of subjects: 63
Study 33744812 — intervention group
Group type: EXPERIMENTAL
Intervention: abiraterone/prednisone
Number of subjects: 63
Study 33744812 — intervention group
Group type: EXPERIMENTAL
Intervention: enzalutamide
Number of subjects: 63
Study 32442298 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose enoxaparin (40 mg daily)
Number of subjects: 50
Study 32442298 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted enoxaparin (1 mg/kg daily)
Number of subjects: 50
Study 34668644 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Number of subjects: 1260
Study 34668644 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1260
Study 36163905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 283
Study 36163905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg once daily
Number of subjects: 283
Study 36163905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg once daily
Number of subjects: 283
Study 36163905 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts combined
Number of subjects: 283
Study 33618657 — intervention group
Group type: EXPERIMENTAL
Intervention: Last kilometre medicine delivery service
Number of subjects: 116
Study 33618657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for ordering medicines
Number of subjects: 116
Study 33618657 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of medicines
Number of subjects: 116
Study 33618657 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay for the service
Number of subjects: 116
Study 33618657 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of demographic factors on preferences
Number of subjects: 116
Study 32797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg day‐1)
Number of subjects: 100
Study 32797125 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 36440058 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera capsules
Number of subjects: 88
Study 36440058 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 88
Study 32105267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg once a day at night for 3 months)
Number of subjects: 100
Study 32105267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33303553 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for COPD with chronic cough (n=16)
Number of subjects: 27
Study 33303553 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for COPD without chronic cough (n=11)
Number of subjects: 27
Study 33303553 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for CRC
Number of subjects: 27
Study 33303553 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for healthy participants
Number of subjects: 27